Stock Updates

A look at a High Market Cap Stock: BioMarin Pharmaceutical Inc., BMRN

BioMarin Pharmaceutical Inc., BMRN is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, BioMarin Pharmaceutical Inc., BMRN  has a market cap of 14197.42. Since its IPO date on the 7/26/1999, BioMarin Pharmaceutical Inc., BMRN performance year to date is -12.67%. Today BioMarin Pharmaceutical Inc., BMRN has gained 3.78%, with a current price of 91.49.

Ownership of the company is 0.60% for insider ownership while institutional ownership is 100.00%. The management of the company have seen the company have a payout ratio of *TBA. Return of assets are at -5.20%, with return on investment at -4.20%.

In terms of debt levels and profit levels, BioMarin Pharmaceutical Inc., BMRN is seeing a long-term debt/equity of 0.29. While Total debt/equity is 0.29. With a profit margin of -20.50%, this is combined with a gross margin of 82.40%, and operating margin of -13.60%. BioMarin Pharmaceutical Inc. ability to meet debt levels, with a current ratio of 2.6, while the quick ratio is 1.8.

For the last year BioMarin Pharmaceutical Inc., BMRN has seen a EPS growth of -17.30%. A performance for the year of -33.51%. The 52-week high is -39.71%, and the 52-week low is 47.28%. The average volume for BioMarin Pharmaceutical Inc., BMRN is 3766145.

With a target price of 111.95, can BioMarin Pharmaceutical Inc., BMRN reach this target? Looking at the value indicators of BioMarin Pharmaceutical Inc., BMRN. BioMarin Pharmaceutical Inc. has a P/E of *TBA and a forward P/E of *TBA. Perhaps the more useful indicator than P/E, is PEG which has a value of *TBA. BioMarin Pharmaceutical Inc. also has a P/S and a P/B of 15.36 and 6.45 respectively. For P/cash, BioMarin Pharmaceutical Inc. has a value of 31.07, while it is *TBA for P/free cash flow.

At the current price of 91.49, BioMarin Pharmaceutical Inc. has a dividend yield of *TBA. We see a return on equity of -8.10%.

Looking more long-term BioMarin Pharmaceutical Inc., is projected to get an EPS growth for the next five years of 25.00%. In the short-term an EPS growth of 54.00% in the next year is forecasted. This is after a EPS growth of -17.30% for this year and for the last five years a -21.30% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Stephen Butters

Leave a Comment